

Andrew J Pollard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1130584/publications.pdf>

Version: 2024-02-01

354
papers

34,453
citations

7551

77
h-index

5227

165
g-index

387
all docs

387
docs citations

387
times ranked

38736
citing authors

#	ARTICLE	IF	CITATIONS
1	Should children be vaccinated against COVID-19?. Archives of Disease in Childhood, 2022, 107, e1.4-e8.	1.0	89
2	Human B Cell Responses to Dominant and Subdominant Antigens Induced by a Meningococcal Outer Membrane Vesicle Vaccine in a Phase I Trial. MSphere, 2022, 7, e0067421.	1.3	5
3	Innovative vaccine approaches—a Keystone Symposia report. Annals of the New York Academy of Sciences, 2022, 1511, 59-86.	1.8	5
4	Adenovirus vectors activate VÎ2⁺ Î³ÎT cells in a type I interferonâ€¢, TNFâ€¢, and ILâ€¢18â€¢dependent manner. European Journal of Immunology, 2022, 52, 835-837.	1.6	3
5	SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell, 2022, 185, 467-484.e15.	13.5	788
6	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet, The, 2022, 399, 521-529.	6.3	314
7	International links between Streptococcus pneumoniae vaccine serotype 4 sequence type (ST) 801 in Northern European shipyard outbreaks of invasive pneumococcal disease. Vaccine, 2022, 40, 1054-1060.	1.7	4
8	A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. Cell, 2022, 185, 916-938.e58.	13.5	164
9	National rates and disparities in childhood vaccination and vaccine-preventable disease during the COVID-19 pandemic: English sentinel network retrospective database study. Archives of Disease in Childhood, 2022, 107, 733-739.	1.0	12
10	Viral vectors expressing group B meningococcal outer membrane proteins induce strong antibody responses but fail to induce functional bactericidal activity. Journal of Infection, 2022, 84, 658-667.	1.7	3
11	CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination. JCI Insight, 2022, 7, .	2.3	6
12	Divergent trajectories of antiviral memory after SARS-CoV-2 infection. Nature Communications, 2022, 13, 1251.	5.8	20
13	Decoupling of omicron variant infections and severe COVID-19. Lancet, The, 2022, 399, 1047-1048.	6.3	22
14	Highly Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe PCR. Journal of Clinical Microbiology, 2022, 60, e0228321.	1.8	5
15	Genetic Susceptibility to Enteric Fever in Experimentally Challenged Human Volunteers. Infection and Immunity, 2022, 90, e0038921.	1.0	5
16	Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. JCI Insight, 2022, 7, .	2.3	26
17	Prevention of Typhoid by Vi Conjugate Vaccine and Achievable Improvements in Household Water, Sanitation, and Hygiene: Evidence From a Cluster-Randomized Trial in Dhaka, Bangladesh. Clinical Infectious Diseases, 2022, 75, 1681-1687.	2.9	9
18	International interlaboratory comparison of Raman spectroscopic analysis of CVD-grown graphene. 2D Materials, 2022, 9, 035010.	2.0	7

#	ARTICLE	IF	CITATIONS
19	Future reporting of vaccine uptake needs to include any change in ethnic or socioeconomic disparities. <i>BMJ, The</i> , 2022, 377, o1233.	3.0	0
20	Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. <i>Cell</i> , 2022, 185, 2116-2131.e18.	13.5	105
21	Viral vector vaccines. <i>Current Opinion in Immunology</i> , 2022, 77, 102210.	2.4	28
22	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial. <i>Lancet, The</i> , 2022, 399, 2212-2225.	6.3	23
23	Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. <i>Cell</i> , 2022, 185, 2422-2433.e13.	13.5	532
24	Mucosal-Associated Invariant T cells exhibit distinct functional signatures associated with protection against typhoid fever. <i>Cellular Immunology</i> , 2022, 378, 104572.	1.4	5
25	Inclusion of a dual signal sequence enhances the immunogenicity of a novel viral vectored vaccine against the capsular group B meningococcus. <i>Cell and Bioscience</i> , 2022, 12, .	2.1	2
26	Immunogenicity of a single 4CMenB vaccine booster in adolescents 11 years after childhood immunisation. <i>Vaccine</i> , 2022, 40, 4453-4463.	1.7	1
27	Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1649.e1-1649.e8.	2.8	20
28	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet, The</i> , 2021, 397, 99-111.	6.3	3,887
29	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. <i>Nature Medicine</i> , 2021, 27, 279-288.	15.2	265
30	A guide to vaccinology: from basic principles to new developments. <i>Nature Reviews Immunology</i> , 2021, 21, 83-100.	10.6	709
31	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. <i>Nature Medicine</i> , 2021, 27, 270-278.	15.2	473
32	What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. <i>Lancet Infectious Diseases, The</i> , 2021, 21, e26-e35.	4.6	500
33	Rapid monitoring of graphene exfoliation using NMR proton relaxation. <i>Nanoscale</i> , 2021, 13, 14518-14524.	2.8	7
34	Using nuclear magnetic resonance proton relaxation to probe the surface chemistry of carbon 2D materials. <i>Nanoscale</i> , 2021, 13, 6389-6393.	2.8	8
35	MAIT cell activation augments adenovirus vector vaccine immunogenicity. <i>Science</i> , 2021, 371, 521-526.	6.0	88
36	Changes in epigenetic profiles throughout early childhood and their relationship to the response to pneumococcal vaccination. <i>Clinical Epigenetics</i> , 2021, 13, 29.	1.8	4

#	ARTICLE	IF	CITATIONS
37	RNA2HLA: HLA-based quality control of RNA-seq datasets. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	11
38	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet, The</i> , 2021, 397, 881-891.	6.3	979
39	Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. <i>Lancet, The</i> , 2021, 397, 1023-1034.	6.3	885
40	Host restriction, pathogenesis and chronic carriage of typhoidal <i>Salmonella</i> . <i>FEMS Microbiology Reviews</i> , 2021, 45, .	3.9	5
41	The importance of international standards for the graphene community. <i>Nature Reviews Physics</i> , 2021, 3, 233-235.	11.9	19
42	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. <i>Nature Communications</i> , 2021, 12, 2055.	5.8	102
43	The antigenic anatomy of SARS-CoV-2 receptor binding domain. <i>Cell</i> , 2021, 184, 2183-2200.e22.	13.5	331
44	Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. <i>Cell</i> , 2021, 184, 2348-2361.e6.	13.5	936
45	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 1351-1362.	6.3	540
46	Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. <i>Cell</i> , 2021, 184, 2201-2211.e7.	13.5	442
47	Antiviral surfaces and coatings and their mechanisms of action. <i>Communications Materials</i> , 2021, 2, .	2.9	149
48	Antibody evasion by the P.1 strain of SARS-CoV-2. <i>Cell</i> , 2021, 184, 2939-2954.e9.	13.5	519
49	Gas Cluster Ion Beam Cleaning of CVD-Grown Graphene for Use in Electronic Device Fabrication. <i>ACS Applied Nano Materials</i> , 2021, 4, 5187-5197.	2.4	5
50	Meningococcal carriage in periods of high and low invasive meningococcal disease incidence in the UK: comparison of UKMenCar1â€“4 cross-sectional survey results. <i>Lancet Infectious Diseases, The</i> , 2021, 21, 677-687.	4.6	24
51	Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. <i>New England Journal of Medicine</i> , 2021, 384, 1885-1898.	13.9	1,077
52	Systems Immunology: Revealing Influenza Immunological Imprint. <i>Viruses</i> , 2021, 13, 948.	1.5	7
53	ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates â€“ Authors' reply. <i>Lancet, The</i> , 2021, 397, 2248.	6.3	9
54	A <i>Salmonella</i> Typhi Controlled Human Infection Study for Assessing Correlation between Bactericidal Antibodies and Protection against Infection Induced by Typhoid Vaccination. <i>Microorganisms</i> , 2021, 9, 1394.	1.6	7

#	ARTICLE	IF	CITATIONS
55	Should we delay covid-19 vaccination in children?. <i>BMJ</i> , The, 2021, 374, n1687.	3.0	15
56	Should we be vaccinating children against COVID-19 in high-income countries?. <i>Expert Review of Vaccines</i> , 2021, 20, 1043-1046.	2.0	8
57	Unlocking thermogravimetric analysis (TGA) in the fight against "Fake graphene" materials. <i>Carbon</i> , 2021, 179, 505-513.	5.4	88
58	Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus. <i>Nature Communications</i> , 2021, 12, 5125.	5.8	16
59	Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial. <i>Lancet</i> , The, 2021, 398, 675-684.	6.3	77
60	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. <i>Lancet HIV</i> , the, 2021, 8, e474-e485.	2.1	190
61	Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. <i>Cell</i> , 2021, 184, 4220-4236.e13.	13.5	630
62	Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. <i>Nature Communications</i> , 2021, 12, 5061.	5.8	150
63	Association of Antibody-Dependent Neutrophil Phagocytosis With Distinct Antibody Glycosylation Profiles Following Typhoid Vaccination. <i>Frontiers in Tropical Diseases</i> , 2021, 2, .	0.5	2
64	Persistence of Antibody After a Vi-Tetanus Toxoid Conjugate Vaccine and Effect of Boosting With a Plain Polysaccharide Vaccine on Vi Antibody and Antigen-Specific B Cells. <i>Frontiers in Tropical Diseases</i> , 2021, 2, .	0.5	1
65	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. <i>Lancet HIV</i> , the, 2021, 8, e568-e580.	2.1	124
66	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T _H 1 response with a diverse TCR repertoire. <i>Science Translational Medicine</i> , 2021, 13, eabj7211.	5.8	80
67	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. <i>Nature Medicine</i> , 2021, 27, 2032-2040.	15.2	900
68	Recent advances in lipopolysaccharide-based glycoconjugate vaccines. <i>Expert Review of Vaccines</i> , 2021, 20, 1515-1538.	2.0	14
69	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). <i>Lancet</i> , The, 2021, 398, 981-990.	6.3	214
70	SIMON: Open-Source Knowledge Discovery Platform. <i>Patterns</i> , 2021, 2, 100178.	3.1	15
71	Vi-specific serological correlates of protection for typhoid fever. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	45
72	Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. <i>Cell</i> , 2021, 184, 5699-5714.e11.	13.5	262

#	ARTICLE	IF	CITATIONS
73	Vaccine nationalism and internationalism: perspectives of COVID-19 vaccine trial participants in the United Kingdom. <i>BMJ Global Health</i> , 2021, 6, e006305.	2.0	14
74	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil. <i>Nature Communications</i> , 2021, 12, 5861.	5.8	38
75	Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination. <i>Lancet, The</i> , 2021, 398, 1683-1684.	6.3	47
76	Incidental findings in UK healthy volunteers screened for a COVID-19 vaccine trial. <i>Clinical and Translational Science</i> , 2021, , .	1.5	1
77	Distinct patterns of whole blood transcriptional responses are induced in mice following immunisation with adenoviral and poxviral vector vaccines encoding the same antigen. <i>BMC Genomics</i> , 2021, 22, 777.	1.2	3
78	<i>Salmonella</i> Typhi Vi capsule prime-boost vaccination induces convergent and functional antibody responses. <i>Science Immunology</i> , 2021, 6, eabj1181.	5.6	7
79	Potential global impacts of alternative dosing regimen and rollout options for the ChAdOx1 nCoV-19 vaccine. <i>Nature Communications</i> , 2021, 12, 6370.	5.8	3
80	Understanding the bonding mechanisms of organic molecules deposited on graphene for biosensing applications. <i>Journal of Chemical Physics</i> , 2021, 155, 174703.	1.2	3
81	TIPICO XI: report of the first series and podcast on infectious diseases and vaccines (aTIPICO). <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4299-4327.	1.4	0
82	Burden of enteric fever at three urban sites in Africa and Asia: a multicentre population-based study. <i>The Lancet Global Health</i> , 2021, 9, e1688-e1696.	2.9	42
83	Two centuries of immunisation in the UK (part II). <i>Archives of Disease in Childhood</i> , 2020, 105, 216-222.	1.0	5
84	Integrated Wafer Scale Growth of Single Crystal Metal Films and High Quality Graphene. <i>ACS Nano</i> , 2020, 14, 13593-13601.	7.3	23
85	Why the elderly appear to be more severely affected by COVID-19: The potential role of immunosenescence and CMV. <i>Reviews in Medical Virology</i> , 2020, 30, e2144.	3.9	98
86	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. <i>Lancet, The</i> , 2020, 396, 467-478.	6.3	2,080
87	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. <i>Lancet, The</i> , 2020, 396, 1979-1993.	6.3	1,196
88	Notice of addendum to Article reporting Oxford trial of ChAdOx1 nCoV-19 vaccine. <i>Lancet, The</i> , 2020, 396, e89.	6.3	2
89	Nanoscale characterization of plasma functionalized graphitic flakes using tip-enhanced Raman spectroscopy. <i>Journal of Chemical Physics</i> , 2020, 153, 184708.	1.2	14
90	Vi-Vaccinations Induce Heterogeneous Plasma Cell Responses That Associate With Protection From Typhoid Fever. <i>Frontiers in Immunology</i> , 2020, 11, 574057.	2.2	11

#	ARTICLE	IF	CITATIONS
91	Mechanical properties of the hollow-wall graphene gyroid lattice. <i>Acta Materialia</i> , 2020, 201, 254-265.	3.8	10
92	Human <i>Salmonella</i> Typhi exposure generates differential multifunctional cross-reactive T cell memory responses against <i>Salmonella</i> Paratyphi and invasive nontyphoidal <i>Salmonella</i> . <i>Clinical and Translational Immunology</i> , 2020, 9, e1178.	1.7	3
93	Payment in challenge studies: ethics, attitudes and a new payment for risk model. <i>Journal of Medical Ethics</i> , 2020, 46, 815-826.	1.0	26
94	Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1390-1400.	4.6	336
95	What time interval is needed between the administration of live attenuated vaccines?. <i>Archives of Disease in Childhood</i> , 2020, 105, 1232-1235.	1.0	0
96	ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 – Authors' reply. <i>Lancet</i> , The, 2020, 396, 1486-1487.	6.3	4
97	Immunogenicity and Reactogenicity of a Reduced Schedule of a 4-component Capsular Group B Meningococcal Vaccine: A Randomized Controlled Trial in Infants. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa143.	0.4	4
98	Priorities for developing respiratory syncytial virus vaccines in different target populations. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	30
99	Raman Fingerprints of Graphene Produced by Anodic Electrochemical Exfoliation. <i>Nano Letters</i> , 2020, 20, 3411-3419.	4.5	59
100	Gas physisorption measurements as a quality control tool for the properties of graphene/graphite powders. <i>Carbon</i> , 2020, 167, 585-595.	5.4	16
101	Determining the Level and Location of Functional Groups on Few-Layer Graphene and Their Effect on the Mechanical Properties of Nanocomposites. <i>ACS Applied Materials & Interfaces</i> , 2020, 12, 13481-13493.	4.0	27
102	The science of vaccine safety: Summary of meeting at Wellcome Trust. <i>Vaccine</i> , 2020, 38, 1869-1880.	1.7	19
103	Progress in the overall understanding of typhoid fever: implications for vaccine development. <i>Expert Review of Vaccines</i> , 2020, 19, 367-382.	2.0	2
104	Bone and joint infections in Oxford: a 10-year retrospective review. <i>Archives of Disease in Childhood</i> , 2020, 105, 515-516.	1.0	1
105	Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines. <i>Vaccine</i> , 2020, 38, 4783-4791.	1.7	102
106	Visualizing variation within Global Pneumococcal Sequence Clusters (GPSCs) and country population snapshots to contextualize pneumococcal isolates. <i>Microbial Genomics</i> , 2020, 6, .	1.0	25
107	Ebola virus glycoprotein stimulates IL-18-dependent natural killer cell responses. <i>Journal of Clinical Investigation</i> , 2020, 130, 3936-3946.	3.9	12
108	Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel. <i>Wellcome Open Research</i> , 2020, 5, 139.	0.9	179

#	ARTICLE	IF	CITATIONS
109	Homologous and heterologous re-challenge with Salmonella Typhi and Salmonella Paratyphi A in a randomised controlled human infection model. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008783.	1.3	15
110	Gene expression profiling reveals insights into infant immunological and febrile responses to group B meningococcal vaccine. <i>Molecular Systems Biology</i> , 2020, 16, e9888.	3.2	7
111	Electronic data capture for large scale typhoid surveillance, household contact tracing, and health utilisation survey: Strategic Typhoid Alliance across Africa and Asia. <i>Wellcome Open Research</i> , 2020, 5, 66.	0.9	8
112	Electronic data capture for large scale typhoid surveillance, household contact tracing, and health utilisation survey: Strategic Typhoid Alliance across Africa and Asia. <i>Wellcome Open Research</i> , 2020, 5, 66.	0.9	9
113	The effect of a single 4CMenB vaccine booster in young people more than ten years after infant immunisation: protocol of an exploratory immunogenicity study. <i>Trials</i> , 2019, 20, 455.	0.7	3
114	Reactive intercalation and oxidation at the buried graphene-germanium interface. <i>APL Materials</i> , 2019, 7, .	2.2	16
115	Investigation of the role of typhoid toxin in acute typhoid fever in a human challenge model. <i>Nature Medicine</i> , 2019, 25, 1082-1088.	15.2	33
116	Two centuries of immunisation in the UK (part 1). <i>Archives of Disease in Childhood</i> , 2019, 105, archdischild-2019-317314.	1.0	2
117	Comparative transcriptomics between species attributes reactogenicity pathways induced by the capsular group B meningococcal vaccine, 4CMenB, to the membrane-bound endotoxin of its outer membrane vesicle component. <i>Scientific Reports</i> , 2019, 9, 13797.	1.6	10
118	Common Genetic Variations Associated with the Persistence of Immunity following Childhood Immunization. <i>Cell Reports</i> , 2019, 27, 3241-3253.e4.	2.9	26
119	The Role and Control of Residual Bulk Oxygen in the Catalytic Growth of 2D Materials. <i>Journal of Physical Chemistry C</i> , 2019, 123, 16257-16267.	1.5	21
120	The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations. <i>Vaccine</i> , 2019, 37, 3190-3198.	1.7	35
121	Identification of regulatory variants associated with genetic susceptibility to meningococcal disease. <i>Scientific Reports</i> , 2019, 9, 6966.	1.6	3
122	Controlled human infection for vaccination against Streptococcus pyogenes (CHIVAS): Establishing a group A Streptococcus pharyngitis human infection study. <i>Vaccine</i> , 2019, 37, 3485-3494.	1.7	31
123	Nanoscale chemical imaging using tip-enhanced Raman spectroscopy. <i>Nature Protocols</i> , 2019, 14, 1169-1193.	5.5	86
124	Tonsillectomy for periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis syndrome (PFAPA). <i>The Cochrane Library</i> , 2019, 2019, CD008669.	1.5	21
125	IgA and IgG1 Specific to Vi Polysaccharide of Salmonella Typhi Correlate With Protection Status in a Typhoid Fever Controlled Human Infection Model. <i>Frontiers in Immunology</i> , 2019, 10, 2582.	2.2	40
126	Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal. <i>New England Journal of Medicine</i> , 2019, 381, 2209-2218.	13.9	147

#	ARTICLE	IF	CITATIONS
127	Treatment responses to Azithromycin and Ciprofloxacin in uncomplicated Salmonella Typhi infection: A comparison of Clinical and Microbiological Data from a Controlled Human Infection Model. PLoS Neglected Tropical Diseases, 2019, 13, e0007955.	1.3	21
128	The Impact of Vaccination and Prior Exposure on Stool Shedding of Salmonella Typhi and Salmonella Paratyphi in 6 Controlled Human Infection Studies. Clinical Infectious Diseases, 2019, 68, 1265-1273.	2.9	26
129	Human challenge trials in vaccine development, Rockville, MD, USA, September 28-30, 2017. Biologicals, 2019, 61, 85-94.	0.5	29
130	UKMenCar4: A cross-sectional survey of asymptomatic meningococcal carriage amongst UK adolescents at a period of low invasive meningococcal disease incidence. Wellcome Open Research, 2019, 4, 118.	0.9	4
131	Diagnostic host gene signature for distinguishing enteric fever from other febrile diseases. EMBO Molecular Medicine, 2019, 11, e10431.	3.3	15
132	UKMenCar4: A cross-sectional survey of asymptomatic meningococcal carriage amongst UK adolescents at a period of low invasive meningococcal disease incidence. Wellcome Open Research, 2019, 4, 118.	0.9	2
133	Management of suspected paediatric meningitis: a multicentre prospective cohort study. Archives of Disease in Childhood, 2018, 103, 1114-1118.	1.0	10
134	Neisseria meningitidis. , 2018, , 747-759.e5.		2
135	MAIT cell clonal expansion and TCR repertoire shaping in human volunteers challenged with Salmonella Paratyphi A. Nature Communications, 2018, 9, 253.	5.8	107
136	Graphene: civil engineering applications start to come to fruition. Proceedings of the Institution of Civil Engineers: Civil Engineering, 2018, 171, 15-15.	0.3	0
137	Change in viral bronchiolitis management in primary care in the UK after the publication of NICE guideline. Thorax, 2018, 73, 674-676.	2.7	10
138	Nanoscale chemical imaging of solid-liquid interfaces using tip-enhanced Raman spectroscopy. Nanoscale, 2018, 10, 1815-1824.	2.8	68
139	The Family Context of Assent: Comparison of Child and Parent Perspectives on Familial Decision-Making. Children and Society, 2018, 32, 266-278.	1.0	0
140	Viral bronchiolitis management in hospitals in the UK. Journal of Clinical Virology, 2018, 104, 29-33.	1.6	11
141	A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK. Vaccine, 2018, 36, 2300-2306.	1.7	12
142	Physicochemical characterisation of reduced graphene oxide for conductive thin films. RSC Advances, 2018, 8, 37540-37549.	1.7	14
143	Differences in Immunization Site Pain in Toddlers Vaccinated With Either the 10- or the 13-Valent Pneumococcal Conjugate Vaccine. Pediatric Infectious Disease Journal, 2018, 37, e103-e106.	1.1	2
144	Global emergence and population dynamics of divergent serotype 3 CC180 pneumococci. PLoS Pathogens, 2018, 14, e1007438.	2.1	74

#	ARTICLE	IF	CITATIONS
145	Antibodies in lymphocyte supernatants can distinguish between neutralising antibodies induced by RSV vaccination and pre-existing antibodies induced by natural infection. <i>Vaccine</i> , 2018, 36, 6988-6994.	1.7	0
146	Typhoid and paratyphoid fever: a call to action. <i>Current Opinion in Infectious Diseases</i> , 2018, 31, 440-448.	1.3	64
147	Laboratory and molecular surveillance of paediatric typhoidal <i>Salmonella</i> in Nepal: Antimicrobial resistance and implications for vaccine policy. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006408.	1.3	70
148	Meningococcal Capsular Group A, C, W, and Y Conjugate Vaccines. , 2018, , 619-643.e11.		7
149	Meningococcal Capsular Group B Vaccines. , 2018, , 644-662.e6.		6
150	<i>Salmonella</i> Typhi Bactericidal Antibodies Reduce Disease Severity but Do Not Protect against Typhoid Fever in a Controlled Human Infection Model. <i>Frontiers in Immunology</i> , 2018, 8, 1916.	2.2	17
151	Incomplete penetrance for isolated congenital asplenia in humans with mutations in translated and untranslated <i>RPSA</i> exons. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E8007-E8016.	3.3	31
152	Change in viral bronchiolitis management in hospitals in the UK after the publication of NICE guideline. <i>Journal of Clinical Virology</i> , 2018, 105, 84-87.	1.6	9
153	Clonal analysis of <i>Salmonella</i> -specific effector T cells reveals serovar-specific and cross-reactive T cell responses. <i>Nature Immunology</i> , 2018, 19, 742-754.	7.0	27
154	Meningococcal Disease. <i>Ulster Medical Journal</i> , 2018, 87, 81-82.	0.2	0
155	High-dimensional assessment of B-cell responses to quadrivalent meningococcal conjugate and plain polysaccharide vaccine. <i>Genome Medicine</i> , 2017, 9, 11.	3.6	15
156	Structural, chemical and electrical characterisation of conductive graphene-polymer composite films. <i>Applied Surface Science</i> , 2017, 403, 403-412.	3.1	25
157	Blood culture-PCR to optimise typhoid fever diagnosis after controlled human infection identifies frequent asymptomatic cases and evidence of primary bacteraemia. <i>Journal of Infection</i> , 2017, 74, 358-366.	1.7	34
158	Production of few-layer graphene by microfluidization. <i>Materials Research Express</i> , 2017, 4, 025604.	0.8	41
159	Memory B cell response to a PCV-13 booster in 3.5 year old children primed with either PCV-7 or PCV-13. <i>Vaccine</i> , 2017, 35, 2701-2708.	1.7	8
160	Non-specific effects of vaccines: plausible and potentially important, but implications uncertain. <i>Archives of Disease in Childhood</i> , 2017, 102, 1077-1081.	1.0	101
161	The Influence of Maternally Derived Antibody and Infant Age at Vaccination on Infant Vaccine Responses. <i>JAMA Pediatrics</i> , 2017, 171, 637.	3.3	332
162	An evaluation of purified <i>Salmonella</i> Typhi protein antigens for the serological diagnosis of acute typhoid fever. <i>Journal of Infection</i> , 2017, 75, 104-114.	1.7	23

#	ARTICLE	IF	CITATIONS
163	Prevalence and decay of maternal pneumococcal and meningococcal antibodies: A meta-analysis of type-specific decay rates. <i>Vaccine</i> , 2017, 35, 5850-5857.	1.7	22
164	Terminology: the first step towards international standardisation of graphene and related 2D materials. <i>Journal of Materials Science</i> , 2017, 52, 13685-13688.	1.7	14
165	Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of <i>Salmonella Typhi</i> : a randomised controlled, phase 2b trial. <i>Lancet, The</i> , 2017, 390, 2472-2480.	6.3	251
166	Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules. <i>Cmaj</i> , 2017, 189, E1276-E1285.	0.9	13
167	Preface. <i>Journal of Infection</i> , 2017, 74, S1.	1.7	0
168	Benchmarking of Viral Bronchiolitis Management by General Practitioners in the United Kingdom. <i>Pediatric, Allergy, Immunology, and Pulmonology</i> , 2017, 30, 69-73.	0.3	2
169	Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England. <i>Lancet Public Health, The</i> , 2017, 2, e367-e374.	4.7	72
170	The STRATAA study protocol: a programme to assess the burden of enteric fever in Bangladesh, Malawi and Nepal using prospective population census, passive surveillance, serological studies and healthcare utilisation surveys. <i>BMJ Open</i> , 2017, 7, e016283.	0.8	61
171	Divergent Memory B Cell Responses in a Mixed Infant Pneumococcal Conjugate Vaccine Schedule. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, e130-e135.	1.1	10
172	Importance of <i>Salmonella Typhi</i> -Responsive CD8+ T Cell Immunity in a Human Typhoid Fever Challenge Model. <i>Frontiers in Immunology</i> , 2017, 8, 208.	2.2	30
173	Challenge of Humans with Wild-type <i>Salmonella enterica</i> Serovar <i>Typhi</i> Elicits Changes in the Activation and Homing Characteristics of Mucosal-Associated Invariant T Cells. <i>Frontiers in Immunology</i> , 2017, 8, 398.	2.2	47
174	The Clinical Application of MicroRNAs in Infectious Disease. <i>Frontiers in Immunology</i> , 2017, 8, 1182.	2.2	134
175	Induction of Cell Cycle and NK Cell Responses by Live-Attenuated Oral Vaccines against Typhoid Fever. <i>Frontiers in Immunology</i> , 2017, 8, 1276.	2.2	10
176	AS03- and MF59-Adjuvanted Influenza Vaccines in Children. <i>Frontiers in Immunology</i> , 2017, 8, 1760.	2.2	109
177	Transcriptomics in Human Challenge Models. <i>Frontiers in Immunology</i> , 2017, 8, 1839.	2.2	41
178	Identification of Novel Serodiagnostic Signatures of Typhoid Fever Using a <i>Salmonella</i> Proteome Array. <i>Frontiers in Microbiology</i> , 2017, 8, 1794.	1.5	32
179	Assessment and Translation of the Antibody-in-Lymphocyte Supernatant (ALS) Assay to Improve the Diagnosis of Enteric Fever in Two Controlled Human Infection Models and an Endemic Area of Nepal. <i>Frontiers in Microbiology</i> , 2017, 8, 2031.	1.5	13
180	Trends in meningococcal disease: challenges for vaccine control when disease is rare. <i>Medical Journal of Australia</i> , 2017, 207, 380-381.	0.8	0

#	ARTICLE	IF	CITATIONS
181	Alternative vaccine administration by powder injection: Needle-free dermal delivery of the glycoconjugate meningococcal group Y vaccine. PLoS ONE, 2017, 12, e0183427.	1.1	7
182	Evaluation of the Clinical and Microbiological Response to Salmonella Paratyphi A Infection in the First Paratyphoid Human Challenge Model. Clinical Infectious Diseases, 2017, 64, 1066-1073.	2.9	60
183	Investigating Systemic Immunity to Typhoid and Paratyphoid Fever: Characterising the Response to Re-challenge in a Controlled Human Infection Model. Open Forum Infectious Diseases, 2017, 4, S227-S228.	0.4	4
184	Duration of intravenous antibiotic therapy for children with acute osteomyelitis or septic arthritis: a feasibility study. Health Technology Assessment, 2017, 21, 1-164.	1.3	19
185	Management of Respiratory Syncytial Virus Bronchiolitis: 2015 Survey of Members of the European Society for Paediatric Infectious Diseases. Canadian Journal of Infectious Diseases and Medical Microbiology, 2016, 2016, 1-5.	0.7	12
186	Non-specific immunological effects of selected routine childhood immunisations: systematic review. BMJ, The, 2016, 355, i5225.	3.0	69
187	Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a. PLoS Neglected Tropical Diseases, 2016, 10, e0004926.	1.3	67
188	The Antibody Response Following a Booster With Either a 10- or 13-valent Pneumococcal Conjugate Vaccine in Toddlers Primed With a 13-valent Pneumococcal Conjugate Vaccine in Early Infancy. Pediatric Infectious Disease Journal, 2016, 35, 787-793.	1.1	14
189	Control of invasive meningococcal disease. International Journal of Evidence-Based Healthcare, 2016, 14, 3-14.	0.1	10
190	Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy. Vaccine, 2016, 34, 6350-6357.	1.7	0
191	Interferon-driven alterations of the host's amino acid metabolism in the pathogenesis of typhoid fever. Journal of Experimental Medicine, 2016, 213, 1061-1077.	4.2	45
192	Salmonella Typhi-specific multifunctional CD8+ T cells play a dominant role in protection from typhoid fever in humans. Journal of Translational Medicine, 2016, 14, 62.	1.8	67
193	Safety and Immunogenicity of Novel Adenovirus Type 26 and Modified Vaccinia Ankara Vectors for Ebola Vaccines. JAMA - Journal of the American Medical Association, 2016, 315, 1610.	3.8	266
194	Harnessing the beneficial heterologous effects of vaccination. Nature Reviews Immunology, 2016, 16, 392-400.	10.6	213
195	Preface. Journal of Infection, 2016, 72, 1.	1.7	0
196	In Situ Graphene Growth Dynamics on Polycrystalline Catalyst Foils. Nano Letters, 2016, 16, 6196-6206.	4.5	62
197	Diagnostic Test Accuracy of a 2-Transcript Host RNA Signature for Discriminating Bacterial vs Viral Infection in Febrile Children. JAMA - Journal of the American Medical Association, 2016, 316, 835.	3.8	263
198	The predicted persistence and kinetics of antibody decline 9 years after pre-school booster vaccination in UK children. Vaccine, 2016, 34, 4221-4228.	1.7	10

#	ARTICLE	IF	CITATIONS
199	Intussusception risk after rotavirus vaccination in England. <i>Vaccine</i> , 2016, 34, 6114.	1.7	1
200	Understanding and Controlling Cu-Catalyzed Graphene Nucleation: The Role of Impurities, Roughness, and Oxygen Scavenging. <i>Chemistry of Materials</i> , 2016, 28, 8905-8915.	3.2	128
201	Metrology for graphene and 2D materials. <i>Measurement Science and Technology</i> , 2016, 27, 092001.	1.4	13
202	B-cell repertoire dynamics after sequential hepatitis B vaccination and evidence for cross-reactive B-cell activation. <i>Genome Medicine</i> , 2016, 8, 68.	3.6	64
203	Developing a new justification for assent. <i>BMC Medical Ethics</i> , 2016, 17, 2.	1.0	30
204	A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. <i>New England Journal of Medicine</i> , 2016, 374, 1635-1646.	13.9	295
205	Prevention of meningococcal disease through vaccination. , 2016, , 91-103.		0
206	Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 1853-1858.	3.3	176
207	RSV vaccine use – the missing data. <i>Expert Review of Vaccines</i> , 2016, 15, 149-152.	2.0	17
208	A quantitative review of healthcare professionals' questions to a local immunization advice service: 4299 enquiries from 3 years. <i>Journal of Public Health</i> , 2016, 38, 578-584.	1.0	1
209	Ethical Criteria for Human Challenge Studies in Infectious Diseases: Table 1.. <i>Public Health Ethics</i> , 2016, 9, 92-103.	0.4	84
210	Covalent Carbene Functionalization of Graphene: Toward Chemical Band-Gap Manipulation. <i>ACS Applied Materials & Interfaces</i> , 2016, 8, 4870-4877.	4.0	49
211	Investigation of CVD graphene topography and surface electrical properties. <i>Surface Topography: Metrology and Properties</i> , 2016, 4, 025001.	0.9	3
212	Enter B and W: two new meningococcal vaccine programmes launched. <i>Archives of Disease in Childhood</i> , 2016, 101, 91-95.	1.0	94
213	Admission to hospital for bronchiolitis in England: trends over five decades, geographical variation and association with perinatal characteristics and subsequent asthma. <i>Archives of Disease in Childhood</i> , 2016, 101, 140-146.	1.0	157
214	Impact of Reducing Complement Inhibitor Binding on the Immunogenicity of Native <i>Neisseria meningitidis</i> Outer Membrane Vesicles. <i>PLoS ONE</i> , 2016, 11, e0148840.	1.1	6
215	Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults. <i>PLoS ONE</i> , 2016, 11, e0165384.	1.1	2
216	The use of systems biology and immunological big data to guide vaccine development. <i>Genome Medicine</i> , 2015, 7, 114.	3.6	10

#	ARTICLE	IF	CITATIONS
217	In-Depth Assessment of Within-Individual and Inter-Individual Variation in the B Cell Receptor Repertoire. <i>Frontiers in Immunology</i> , 2015, 6, 531.	2.2	92
218	Oral Wild-Type Salmonella Typhi Challenge Induces Activation of Circulating Monocytes and Dendritic Cells in Individuals Who Develop Typhoid Disease. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003837.	1.3	18
219	An OMV Vaccine Derived from a Capsular Group B Meningococcus with Constitutive FetA Expression: Preclinical Evaluation of Immunogenicity and Toxicity. <i>PLoS ONE</i> , 2015, 10, e0134353.	1.1	9
220	Effect of disorder on Raman scattering of single-layer MoS_2 . <i>Physical Review B</i> , 2015, 91, .	1.1	553
221	Analysis of B Cell Repertoire Dynamics Following Hepatitis B Vaccination in Humans, and Enrichment of Vaccine-specific Antibody Sequences. <i>EBioMedicine</i> , 2015, 2, 2070-2079.	2.7	92
222	The capsular group B meningococcal vaccine, 4CMenB: clinical experience and potential efficacy. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 131-142.	1.4	20
223	Nucleation Control for Large, Single Crystalline Domains of Monolayer Hexagonal Boron Nitride via Si-Doped Fe Catalysts. <i>Nano Letters</i> , 2015, 15, 1867-1875.	4.5	139
224	Activation of Salmonella Typhi-Specific Regulatory T Cells in Typhoid Disease in a Wild-Type S. Typhi Challenge Model. <i>PLoS Pathogens</i> , 2015, 11, e1004914.	2.1	50
225	Understanding paratyphoid infection: study protocol for the development of a human model of Salmonella enterica serovar Paratyphi A challenge in healthy adult volunteers. <i>BMJ Open</i> , 2015, 5, e007481-e007481.	0.8	16
226	Immunogenicity of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine compared to standard-dose diphtheria, tetanus, acellular pertussis when used as a pre-school booster in UK children: A 5-year follow-up of a randomised controlled study. <i>Vaccine</i> , 2015, 33, 4579-4585.	1.7	11
227	Removal of Organic Contamination from Graphene with a Controllable Mass-Selected Argon Gas Cluster Ion Beam. <i>Journal of Physical Chemistry C</i> , 2015, 119, 17836-17841.	1.5	24
228	Design, recruitment, and microbiological considerations in human challenge studies. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 840-851.	4.6	107
229	Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial. <i>BMJ</i> , The, 2015, 350, h1554-h1554.	3.0	27
230	BCR repertoire sequencing: different patterns of B cell activation after two Meningococcal vaccines. <i>Immunology and Cell Biology</i> , 2015, 93, 885-895.	1.0	83
231	Searching for the human genetic factors standing in the way of universally effective vaccines. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2015, 370, 20140341.	1.8	38
232	Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months. <i>Cmaj</i> , 2015, 187, E215-E223.	0.9	29
233	Group B meningococcal vaccine science and policy. <i>Journal of Infection</i> , 2015, 71, S15-S20.	1.7	6
234	Investigations of the effect of SiC growth face on graphene thickness uniformity and electronic properties. <i>Surface Topography: Metrology and Properties</i> , 2015, 3, 015001.	0.9	5

#	ARTICLE	IF	CITATIONS
235	Probing individual point defects in graphene via near-field Raman scattering. <i>Nanoscale</i> , 2015, 7, 19413-19418.	2.8	35
236	Chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. <i>Science Translational Medicine</i> , 2015, 7, 300ra126.	5.8	109
237	Needle-Free Dermal Delivery of a Diphtheria Toxin CRM ₁₉₇ Mutant on Potassium-Doped Hydroxyapatite Microparticles. <i>Vaccine Journal</i> , 2015, 22, 586-592.	3.2	10
238	Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategy. <i>Journal of Infection</i> , 2015, 71, 43-52.	1.7	61
239	A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial. <i>Journal of Infection</i> , 2015, 71, 326-337.	1.7	40
240	Childhood meningitis in the conjugate vaccine era: a prospective cohort study. <i>Archives of Disease in Childhood</i> , 2015, 100, 292-294.	1.0	37
241	Identification of Antigen-Specific B Cell Receptor Sequences Using Public Repertoire Analysis. <i>Journal of Immunology</i> , 2015, 194, 252-261.	0.4	115
242	Rapidly Escalating Hepcidin and Associated Serum Iron Starvation Are Features of the Acute Response to Typhoid Infection in Humans. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0004029.	1.3	38
243	Neuronal Antibodies in Children with or without Narcolepsy following H1N1-AS03 Vaccination. <i>PLoS ONE</i> , 2015, 10, e0129555.	1.1	17
244	Adjuvant Effects Elicited by Novel Oligosaccharide Variants of Detoxified Meningococcal Lipopolysaccharides on <i>Neisseria meningitidis</i> Recombinant PorA Protein: A Comparison in Mice. <i>PLoS ONE</i> , 2014, 9, e115713.	1.1	3
245	Quantitative characterization of defect size in graphene using Raman spectroscopy. <i>Applied Physics Letters</i> , 2014, 105, .	1.5	61
246	Association between population prevalence of smoking and incidence of meningococcal disease in Norway, Sweden, Denmark and the Netherlands between 1975 and 2009: a population-based time series analysis. <i>BMJ Open</i> , 2014, 4, e003312.	0.8	15
247	An Outpatient, Ambulant-Design, Controlled Human Infection Model Using Escalating Doses of <i>Salmonella Typhi</i> Challenge Delivered in Sodium Bicarbonate Solution. <i>Clinical Infectious Diseases</i> , 2014, 58, 1230-1240.	2.9	126
248	The serodominant secreted effector protein of <i>Salmonella</i> , SseB, is a strong CD4 antigen containing an immunodominant epitope presented by diverse HLA class II alleles. <i>Immunology</i> , 2014, 143, 438-446.	2.0	32
249	Polysaccharide-specific B cell responses to vaccination in humans. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1661-1668.	1.4	42
250	Persistence of Bactericidal Antibodies to 5 Years of Age After Immunization With Serogroup B Meningococcal Vaccines at 6, 8, 12 and 40 Months of Age. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 760-766.	1.1	34
251	Typhoid epidemiology, diagnostics and the human challenge model. <i>Current Opinion in Gastroenterology</i> , 2014, 30, 7-17.	1.0	40
252	The Effect of Chronic Cytomegalovirus Infection on Pneumococcal Vaccine Responses. <i>Journal of Infectious Diseases</i> , 2014, 209, 1635-1641.	1.9	19

#	ARTICLE	IF	CITATIONS
253	Group B meningococcal vaccine: recommendations for UK use. <i>Lancet, The</i> , 2014, 383, 1103-1104.	6.3	24
254	The challenge of enteric fever. <i>Journal of Infection</i> , 2014, 68, S38-S50.	1.7	49
255	A vaccine against serogroup B <i>Neisseria meningitidis</i> : dealing with uncertainty. <i>Lancet Infectious Diseases, The</i> , 2014, 14, 426-434.	4.6	50
256	High-Resolution Electrochemical and Topographical Imaging Using Batch-Fabricated Cantilever Probes. <i>Analytical Chemistry</i> , 2014, 86, 5143-5149.	3.2	39
257	Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. <i>Lancet, The</i> , 2014, 384, 2123-2131.	6.3	247
258	Editorials. <i>Indian Pediatrics</i> , 2014, 51, 445-450.	0.2	0
259	Advancing the management and control of typhoid fever: A review of the historical role of human challenge studies. <i>Journal of Infection</i> , 2014, 68, 405-418.	1.7	40
260	Hospital admission rates for meningitis and septicaemia caused by <i>Haemophilus influenzae</i> , <i>Neisseria meningitidis</i> , and <i>Streptococcus pneumoniae</i> in children in England over five decades: a population-based observational study. <i>Lancet Infectious Diseases, The</i> , 2014, 14, 397-405.	4.6	96
261	Studying the antibody repertoire after vaccination: practical applications. <i>Trends in Immunology</i> , 2014, 35, 319-331.	2.9	110
262	Pneumococcal Serotype-Specific Antibodies Persist through Early Childhood after Infant Immunization: Follow-Up from a Randomized Controlled Trial. <i>PLoS ONE</i> , 2014, 9, e91413.	1.1	12
263	Evaluation of the Induction of Immune Memory following Infant Immunisation with Serogroup C <i>Neisseria meningitidis</i> Conjugate Vaccines – Exploratory Analyses within a Randomised Controlled Trial. <i>PLoS ONE</i> , 2014, 9, e101672.	1.1	11
264	The B-cell response to a primary and booster course of MenACWY-CRM197 vaccine administered at 2, 4 and 12 months of age. <i>Vaccine</i> , 2013, 31, 2441-2448.	1.7	16
265	Emergence of serogroup X meningococcal disease in Africa: Need for a vaccine. <i>Vaccine</i> , 2013, 31, 2852-2861.	1.7	90
266	Prevalence and Genetic Analysis of Phenotypically Vi- Negative <i>Salmonella Typhi</i> Isolates in Children from Kathmandu, Nepal. <i>Journal of Tropical Pediatrics</i> , 2013, 59, 317-320.	0.7	10
267	Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination. <i>Archives of Disease in Childhood</i> , 2013, 98, 686-691.	1.0	23
268	Prospects for prevention of <i>Salmonella</i> infection in children through vaccination. <i>Current Opinion in Infectious Diseases</i> , 2013, 26, 254-262.	1.3	26
269	Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease. <i>Archives of Disease in Childhood</i> , 2013, 98, 248-251.	1.0	18
270	Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose. <i>Cmaj</i> , 2013, 185, E715-E724.	0.9	68

#	ARTICLE	IF	CITATIONS
271	Seroprevalence and Placental Transmission of Maternal Antibodies Specific for <i>Neisseria meningitidis</i> Serogroups A, C, Y and W135 and Influence of Maternal Antibodies on the Immune Response to a Primary Course of MenACWY-CRM Vaccine in the United Kingdom. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, 768-776.	1.1	15
272	Bactericidal Antibody Persistence 2 Years After Immunization With 2 Investigational Serogroup B Meningococcal Vaccines at 6, 8 and 12 Months and Immunogenicity of Preschool Booster Doses. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, 1116-1121.	1.1	38
273	Phase II Study of a Three-dose Primary Vaccination Course of DTPa-IPV/Hib-MenC-TT Followed by a 12-month Hib-MenC-TT Booster in Healthy Infants. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, 675-681.	1.1	5
274	Single Nucleotide Polymorphisms in the Toll-Like Receptor 3 and CD44 Genes Are Associated with Persistence of Vaccine-Induced Immunity to the Serogroup C Meningococcal Conjugate Vaccine. <i>Vaccine Journal</i> , 2012, 19, 295-303.	3.2	17
275	Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 573-82.	3.8	247
276	B Cell Memory to a Serogroup C Meningococcal Conjugate Vaccine in Childhood and Response to Booster: Little Association with Serum IgG Antibody. <i>Journal of Immunology</i> , 2012, 189, 2673-2681.	0.4	24
277	Assessment of T-dependent and T-independent immune responses in cattle using a B cell ELISPOT assay. <i>Veterinary Research</i> , 2012, 43, 68.	1.1	16
278	Persistence of Antibody Response Following a Booster Dose of Hib-MenC-TT Glycoconjugate Vaccine to Five Years. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 1069-1073.	1.1	12
279	<i>Neisseria meningitidis</i> . , 2012, , 730-741.e7.		1
280	<i>Expert Review of Vaccines</i> 10-year anniversary issue. <i>Expert Review of Vaccines</i> , 2011, 10, 1489-1491.	2.0	0
281	Long-term protection after immunization with proteinâ€“polysaccharide conjugate vaccines in infancy. <i>Expert Review of Vaccines</i> , 2011, 10, 673-684.	2.0	49
282	Persistence of Serum Bactericidal Antibody One Year After a Booster Dose of Either a Glycoconjugate or a Plain Polysaccharide Vaccine Against Serogroup C <i>Neisseria meningitidis</i> Given to Adolescents Previously Immunized With a Glycoconjugate Vaccine. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, e203-e208.	1.1	13
283	Persistence of Immunity Following a Booster Dose of Haemophilus Influenzae Type B-Meningococcal Serogroup C Glycoconjugate Vaccine. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 197-202.	1.1	28
284	Antibody Repertoire: Embracing Diversity. <i>Science Translational Medicine</i> , 2011, 3, 93ps32.	5.8	6
285	Multifunctional Nanoprobes for Nanoscale Chemical Imaging and Localized Chemical Delivery at Surfaces and Interfaces. <i>Angewandte Chemie - International Edition</i> , 2011, 50, 9638-9642.	7.2	256
286	Comparison of a limiting dilution assay and ELISpot for detection of memory B-cells before and after immunisation with a protein-polysaccharide conjugate vaccine in children. <i>Journal of Immunological Methods</i> , 2010, 358, 46-55.	0.6	12
287	Challenges in immunisation against bacterial infection in children. <i>Early Human Development</i> , 2010, 86, 695-701.	0.8	10
288	Supramolecular Assemblies Formed on an Epitaxial Graphene Superstructure. <i>Angewandte Chemie - International Edition</i> , 2010, 49, 1794-1799.	7.2	108

#	ARTICLE	IF	CITATIONS
289	Multicenter, Open-Label, Randomized Phase II Controlled Trial of an Investigational Recombinant Meningococcal Serogroup B Vaccine With and Without Outer Membrane Vesicles, Administered in Infancy. <i>Clinical Infectious Diseases</i> , 2010, 51, 1127-1137.	2.9	235
290	The epidemiology of meningococcal disease and the impact of vaccines. <i>Expert Review of Vaccines</i> , 2010, 9, 285-298.	2.0	116
291	Serogroup B meningococcal vaccines—“an unfinished story. <i>Lancet Infectious Diseases</i> , The, 2010, 10, 112-124.	4.6	107
292	Immunogenicity of Two Investigational Serogroup B Meningococcal Vaccines in the First Year of Life. <i>Pediatric Infectious Disease Journal</i> , 2010, 29, e71-e79.	1.1	151
293	Challenges and progress in the development of a serogroup B meningococcal vaccine. <i>Expert Review of Vaccines</i> , 2009, 8, 729-745.	2.0	21
294	Long-Term Immunological Follow-Up of Children with <i>Haemophilus influenzae</i> Serotype b Vaccine Failure in the United Kingdom. <i>Clinical Infectious Diseases</i> , 2009, 49, 372-380.	2.9	24
295	Kinetics of the Natural, Humoral Immune Response to <i>Salmonella enterica</i> Serovar Typhi in Kathmandu, Nepal. <i>Vaccine Journal</i> , 2009, 16, 1413-1419.	3.2	57
296	How Does Graphene Grow? Easy Access to Well-Ordered Graphene Films. <i>Small</i> , 2009, 5, 2291-2296.	5.2	40
297	Plasma and memory B-cell kinetics in infants following a primary schedule of CRM ₁₉₇ -conjugated serogroup C meningococcal polysaccharide vaccine. <i>Immunology</i> , 2009, 127, 134-143.	2.0	37
298	Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. <i>Nature Reviews Immunology</i> , 2009, 9, 213-220.	10.6	389
299	Appearance of peripheral blood plasma cells and memory B cells in a primary and secondary immune response in humans. <i>Blood</i> , 2009, 114, 4998-5002.	0.6	107
300	Immunogenicity of a Tetravalent Meningococcal Glycoconjugate Vaccine in Infants. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 173-84.	3.8	194
301	Sustaining immunity after immunization against encapsulated bacteria. <i>Hum Vaccin</i> , 2008, 4, 309-312.	2.4	12
302	The Magnitude of the Antibody and Memory B Cell Responses during Priming with a Protein-Polysaccharide Conjugate Vaccine in Human Infants Is Associated with the Persistence of Antibody and the Intensity of Booster Response. <i>Journal of Immunology</i> , 2008, 180, 2165-2173.	0.4	101
303	<i>Haemophilus influenzae</i> Type b Vaccine Failure in Children Is Associated with Inadequate Production of High-Quality Antibody. <i>Clinical Infectious Diseases</i> , 2008, 46, 186-192.	2.9	72
304	Serotype-Specific and Age-Dependent Generation of Pneumococcal Polysaccharide-Specific Memory B-Cell and Antibody Responses to Immunization with a Pneumococcal Conjugate Vaccine. <i>Vaccine Journal</i> , 2008, 15, 182-193.	3.2	57
305	<i>Neisseria meningitidis</i> . , 2008, , 734-743.		2
306	Vaccines for the Prevention of Admission to the Pediatric Intensive Care Unit. , 2008, , 143-175.		0

#	ARTICLE	IF	CITATIONS
307	The Role Familiarity With Science and Medicine Plays in Parents's Decision Making About Enrolling a Child in Vaccine Research. <i>Qualitative Health Research</i> , 2007, 17, 311-322.	1.0	35
308	Vi polysaccharide-protein conjugate vaccine for the prevention of typhoid fever in children: hope or hype?. <i>Expert Review of Vaccines</i> , 2007, 6, 293-295.	2.0	12
309	Social Mixing with Other Children during Infancy Enhances Antibody Response to a Pneumococcal Conjugate Vaccine in Early Childhood. <i>Vaccine Journal</i> , 2007, 14, 593-599.	3.2	23
310	Emergency management of meningococcal disease: eight years on. <i>Archives of Disease in Childhood</i> , 2007, 92, 283-286.	1.0	56
311	New combination vaccines still need a boost. <i>Archives of Disease in Childhood</i> , 2007, 92, 1-2.	1.0	7
312	Childhood immunisation: what is the future?. <i>Archives of Disease in Childhood</i> , 2007, 92, 426-433.	1.0	21
313	Reconsideration of the Use of Meningococcal Polysaccharide Vaccine. <i>Pediatric Infectious Disease Journal</i> , 2007, 26, 716-722.	1.1	79
314	A New Combination Haemophilus influenzae Type B and Neisseria meningitidis Serogroup C-Tetanus Toxoid Conjugate Vaccine for Primary Immunization of Infants. <i>Pediatric Infectious Disease Journal</i> , 2007, 26, 1057-1059.	1.1	33
315	Immunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine in preterm UK infants. <i>Vaccine</i> , 2007, 25, 264-271.	1.7	44
316	CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells. <i>Blood</i> , 2006, 108, 2642-2647.	0.6	99
317	Course of Disease and Clinical Management. , 2006, , 481-517.		1
318	The kinetics and phenotype of the human B-cell response following immunization with a heptavalent pneumococcal-CRM197 conjugate vaccine. <i>Immunology</i> , 2006, 119, 328-337.	2.0	52
319	Effectiveness Analyses May Underestimate Protection of Infants after Group C Meningococcal Immunization. <i>Journal of Infectious Diseases</i> , 2006, 194, 231-237.	1.9	17
320	Effect of needle size on immunogenicity and reactogenicity of vaccines in infants: randomised controlled trial. <i>BMJ: British Medical Journal</i> , 2006, 333, 571.	2.4	62
321	Serogroup C Meningococcal Glycoconjugate Vaccine in Adolescents: Persistence of Bactericidal Antibodies and Kinetics of the Immune Response to a Booster Vaccine More Than 3 Years after Immunization. <i>Clinical Infectious Diseases</i> , 2006, 43, 1387-1394.	2.9	77
322	Experience with MCV-4, a meningococcal, diphtheria toxoid conjugate vaccine against serogroups A, C, Y and W-135. <i>Expert Review of Vaccines</i> , 2006, 5, 445-459.	2.0	11
323	Lack of Serum Bactericidal Activity in Preschool Children Two Years After a Single Dose of Serogroup C Meningococcal Polysaccharide-Protein Conjugate Vaccine. <i>Pediatric Infectious Disease Journal</i> , 2005, 24, 128-131.	1.1	91
324	Immunogenicity and Immunologic Memory of Meningococcal C Conjugate Vaccine in Premature Infants. <i>Pediatric Infectious Disease Journal</i> , 2005, 24, 966-968.	1.1	24

#	ARTICLE	IF	CITATIONS
325	Immunogenicity and Safety of a Combination Pneumococcal-Meningococcal Vaccine in Infants. JAMA - Journal of the American Medical Association, 2005, 293, 1751.	3.8	63
326	Rapid and Fatal Meningococcal Disease Due to a Strain of Neisseria meningitidis Containing the Capsule Null Locus. Clinical Infectious Diseases, 2005, 40, e38-e42.	2.9	63
327	Immunological Memory. JAMA - Journal of the American Medical Association, 2005, 294, 3019.	3.8	96
328	Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infectious Diseases, The, 2005, 5, 21-30.	4.6	163
329	Clinical trials: consent in children. Expert Review of Vaccines, 2005, 4, 1-3.	2.0	2
330	Global Epidemiology of Meningococcal Disease and Vaccine Efficacy. Pediatric Infectious Disease Journal, 2004, 23, S274-S279.	1.1	142
331	Disease Susceptibility to ST11 Complex Meningococci Bearing Serogroup C or W135 Polysaccharide Capsules, North America. Emerging Infectious Diseases, 2004, 10, 1812-1815.	2.0	30
332	Eligibility of overseas visitors and people of uncertain residential status for NHS treatment. BMJ: British Medical Journal, 2004, 329, 346-349.	2.4	25
333	Differential post-transcriptional activation of human phagocytes by different Pseudomonas aeruginosa isolates. Cellular Microbiology, 2004, 6, 639-650.	1.1	13
334	Meningococcal Vaccines. Paediatric Drugs, 2004, 6, 251-266.	1.3	16
335	Immunogenicity and safety of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine as a pre-school booster in UK children. Vaccine, 2004, 22, 4262-4269.	1.7	45
336	Depressive pseudodementia in a child with autism. Developmental Medicine and Child Neurology, 2004, 46, 485-9.	1.1	3
337	Global epidemiology of meningococcal disease and vaccine efficacy. Pediatric Infectious Disease Journal, 2004, 23, S274-9.	1.1	102
338	W135 in Africa: origins, problems and perspectives. Travel Medicine and Infectious Disease, 2003, 1, 19-28.	1.5	15
339	Epidemic meningococcal disease in sub-Saharan Africa-towards a sustainable solution?. Lancet Infectious Diseases, The, 2003, 3, 68-70.	4.6	13
340	Immunologic memory with no detectable bactericidal antibody response to a first dose of meningococcal serogroup C conjugate vaccine at four years. Pediatric Infectious Disease Journal, 2003, 22, 659-660.	1.1	23
341	Immunologic memory with no detectable bactericidal antibody response to a first dose of meningococcal serogroup C conjugate vaccine at four years. Pediatric Infectious Disease Journal, 2003, 22, 659-61.	1.1	11
342	Meningococcal vaccines. Expert Review of Vaccines, 2002, 1, 75-84.	2.0	13

#	ARTICLE	IF	CITATIONS
343	The meningococcus tamed?. Archives of Disease in Childhood, 2002, 87, 13-17.	1.0	20
344	Evaluation of a Diagnostic Polymerase Chain Reaction Assay for <i>Neisseria meningitidis</i> in North America and Field Experience During an Outbreak. Archives of Pathology and Laboratory Medicine, 2002, 126, 1209-1215.	1.2	24
345	Vaccine prevention of meningococcal disease, coming soon?. Vaccine, 2001, 20, 666-687.	1.7	102
346	NONOPSONIC PHAGOCYTOSIS OF PSEUDOMONAS AERUGINOSA: INSIGHTS FROM AN INFANT WITH LEUKOCYTE ADHESION DEFICIENCY. Pediatric Infectious Disease Journal, 2001, 20, 452-454.	1.1	14
347	Emerging infectious diseases in the 21st century. Current Opinion in Infectious Diseases, 2000, 13, 265-275.	1.3	12
348	Vaccines for prevention of meningococcal disease. Pediatric Infectious Disease Journal, 2000, 19, 333-344.	1.1	74
349	Assessment of immune response to meningococcal disease: comparison of a whole-blood assay and the serum bactericidal assay. Microbial Pathogenesis, 1999, 27, 207-214.	1.3	40
350	Humoral Immune Responses to <i>Neisseria meningitidis</i> in Children. Infection and Immunity, 1999, 67, 2441-2451.	1.0	46
351	Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC-202012/01 (B.1.1.7). SSRN Electronic Journal, 0, , .	0.4	36
352	Single Dose Administration, and The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine. SSRN Electronic Journal, 0, , .	0.4	10
353	Reduced Neutralization of SARS-CoV-2 B.1.1.7 Variant from Naturally Acquired and Vaccine Induced Antibody Immunity. SSRN Electronic Journal, 0, , .	0.4	2
354	Factors influencing participation in controlled human infection models: a pooled analysis from six enteric fever studies. Wellcome Open Research, 0, 4, 153.	0.9	6